Webster M A, Hutchinson J N, Rauh M J, Muthuswamy S K, Anton M, Tortorice C G, Cardiff R D, Graham F L, Hassell J A, Muller W J
Institute for Molecular Biology and Biotechnology, and Department of Biology, McMaster University, Hamilton, Ontario, Canada.
Mol Cell Biol. 1998 Apr;18(4):2344-59. doi: 10.1128/MCB.18.4.2344.
Transgenic mice expressing the polyomavirus (PyV) middle T antigen (MT) develop multifocal mammary tumors which frequently metastasize to the lung. The potent transforming activity of PyV MT is correlated with its capacity to activate and associate with a number of signaling molecules, including the Src family tyrosine kinases, the 85-kDa Src homology 2 subunit of the phosphatidylinositol 3' (PI-3') kinase, and the Shc adapter protein. To uncover the role of these signaling proteins in MT-mediated mammary tumorigenesis, we have generated transgenic mice that express mutant PyV MT antigens decoupled from either the Shc or the PI-3' kinase signaling pathway. In contrast to the rapid induction of metastatic mammary tumors observed in the strains expressing wild-type PyV MT, mammary epithelial cell-specific expression of either mutant PyV MT resulted in the induction of extensive mammary epithelial hyperplasias. The mammary epithelial hyperplasias expressing the mutant PyV MT defective in recruiting the PI-3' kinase were highly apoptotic, suggesting that recruitment of PI-3' kinase by MT affects cell survival. Whereas the initial phenotypes observed in both strains were global mammary epithelial hyperplasias, focal mammary tumors eventually arose in all female transgenic mice. Genetic and biochemical analyses of tumorigenesis in the transgenic strains expressing the PyV MT mutant lacking the Shc binding site revealed that a proportion of the metastatic tumors arising in these mice displayed evidence of reversion of the mutant Shc binding site. In contrast, no evidence of reversion of the PI-3' kinase binding site was noted in tumors derived from the strains expressing the PI-3' kinase binding site MT mutant. Tumor progression in both mutant strains was further correlated with upregulation of the epidermal growth factor receptor family members which are known to couple to the PI-3' kinase and Shc signaling pathways. Taken together, these observations suggest that PyV MT-mediated tumorigenesis requires activation of both Shc and PI-3' kinase, which appear to be required for stimulation of cell proliferation and survival signaling pathways, respectively.
表达多瘤病毒(PyV)中T抗原(MT)的转基因小鼠会发生多灶性乳腺肿瘤,且这些肿瘤常常转移至肺部。PyV MT强大的转化活性与其激活并与多种信号分子结合的能力相关,这些信号分子包括Src家族酪氨酸激酶、磷脂酰肌醇3'(PI-3')激酶的85-kDa Src同源2亚基以及Shc衔接蛋白。为了揭示这些信号蛋白在MT介导的乳腺肿瘤发生中的作用,我们构建了表达与Shc或PI-3'激酶信号通路解偶联的突变型PyV MT抗原的转基因小鼠。与在表达野生型PyV MT的品系中观察到的转移性乳腺肿瘤的快速诱导不同,任一突变型PyV MT的乳腺上皮细胞特异性表达均导致广泛的乳腺上皮增生。表达在募集PI-3'激酶方面存在缺陷的突变型PyV MT的乳腺上皮增生具有高度凋亡性,这表明MT对PI-3'激酶的募集影响细胞存活。虽然在两个品系中最初观察到的表型都是全身性乳腺上皮增生,但所有雌性转基因小鼠最终都出现了局灶性乳腺肿瘤。对表达缺乏Shc结合位点的PyV MT突变体的转基因品系中的肿瘤发生进行的遗传学和生化分析表明,这些小鼠中出现的一部分转移性肿瘤显示出突变的Shc结合位点发生回复的证据。相比之下,在源自表达PI-3'激酶结合位点MT突变体的品系的肿瘤中,未发现PI-3'激酶结合位点发生回复的证据。两个突变品系中的肿瘤进展还与表皮生长因子受体家族成员的上调相关,已知这些成员与PI-3'激酶和Shc信号通路偶联。综上所述,这些观察结果表明,PyV MT介导的肿瘤发生需要Shc和PI-3'激酶的激活,它们似乎分别是刺激细胞增殖和存活信号通路所必需的。